US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp

Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push

The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform

Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease

By cutting pain crises & boosting haemoglobin

Freudenberg Medical launches CleanAssure cleanroom for sterile single-use assemblies

It is actually a new ISO Class 5 controlled cleanroom designed to deliver washed, dried, and gamma-sterilized single-use assemblies ready for immediate use.

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

Zyax Chem takes 26% stake in Gaymed Labs

Targets high-growth eye care expansion push